Azenta Introduces Revolutionary Long-Read Genome Sequencing Test
In a groundbreaking move, Azenta, Inc. (Nasdaq: AZTA) has launched a long-read Whole Genome Sequencing (WGS) test designed specifically for clinical applications. This innovative test marks Azenta as the first commercial provider to garner regulatory approval within the United States, paving the way for enhanced diagnostics in the realm of genetic analysis.
Overcoming Traditional Sequencing Limitations
Conventional short-read sequencing methods frequently encounter challenges when it comes to identifying genetic variations in repetitive genome regions. These areas are pivotal in many rare diseases and can considerably impede accurate diagnosis, thus limiting treatment options. Unlike these traditional approaches, Azenta's newly approved test employs PacBio's Revio sequencer, which specializes in generating long and highly precise HiFi sequencing reads. This allows for exploration of regions that have been difficult or impossible to analyze using shorter reads.
How Does This New Test Enhance Genetic Detection?
Conducted at Azenta Life Sciences’ state-of-the-art clinical genomics laboratory, which is both CLIA certified and CAP accredited, this test offers comprehensive detection of complex genomic alterations. Such advancements mean that healthcare professionals can identify the intricate genetic factors associated with rare diseases, which often elude traditional testing methods. With this enhanced capability, the genome can be viewed with unprecedented detail, greatly improving diagnostic outcomes.
Expert Insights on the New Test
Dr. Ginger Zhou, Senior Vice President and General Manager of GENEWIZ Multiomics and Synthesis Solutions at Azenta Life Sciences, expressed enthusiasm about the clinical-grade long-read sequencing test. “This technology signifies a monumental leap in understanding the genetic underpinnings of rare diseases,” she said. The ability to capture extensive DNA segments from a single read means that researchers might discover subtle genetic variations previously undetectable.
The Role of Advanced Technology
Christian Henry, President and CEO of PacBio, highlighted the significant impact of their technology on the realm of clinical genomics. “The Revio sequencer's highly accurate HiFi reads offer researchers deeper insights into the complexities of rare diseases,” he noted. Azenta’s collaboration with PacBio is a notable milestone in enhancing clinical applications in genomics.
Learn More About the Test
For those eager to learn more about the Long-Read Whole Genome Sequencing Test, Azenta will be featured at booth #422 during the American Society of Human Genetics (ASHG) Conference. Attendees are invited to gain insights and connect with experts from November 5-9.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) stands at the forefront of life sciences solutions globally, committed to advancing impactful breakthroughs and accelerating therapies to market. The comprehensive suite of services provided by Azenta includes reliable cold-chain sample management and multiomics solutions, catering to drug development, clinical research, and advanced cell therapies. Their clientele includes leading pharmaceutical and biotech firms, along with prominent academic institutions worldwide.
Global Presence and Commitment
Headquartered in Burlington, MA, Azenta maintains a robust operation footprint across North America, Europe, and Asia. The dedicated team works to deliver exemplary products and services through industry-leading brands that are instrumental in improving biosample management and genomic research.
Frequently Asked Questions
What is the long-read Whole Genome Sequencing test?
This test is a clinical application that uses advanced sequencing technology to identify genetic variants and alterations in the genome that are often missed by traditional methods.
How does this test benefit rare disease diagnostics?
The long-read WGS test provides comprehensive insights and accurate detection of complex genomic alterations, significantly enhancing diagnostic precision for rare diseases.
Which technology is utilized for the sequencing?
The test utilizes PacBio's Revio sequencer, known for producing long and highly accurate HiFi reads.
Where can I learn more about Azenta's genomic services?
Further information can be gathered at their exhibition booth during the American Society of Human Genetics (ASHG) Conference or via the Azenta website.
What is Azenta's mission in the life sciences sector?
Azenta aims to facilitate breakthroughs in life sciences by providing reliable sample management and genomic services, thereby accelerating the development and delivery of new therapies.
